Alkem Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
May 29, 2024 at 04:43 am
Share
Alkem Laboratories Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 29,358.2 million compared to INR 29,026 million a year ago. Revenue was INR 30,239.9 million compared to INR 29,712.7 million a year ago. Net income was INR 2,935.6 million compared to INR 709.8 million a year ago. Basic earnings per share from continuing operations was INR 24.55 compared to INR 5.94 a year ago. Diluted earnings per share from continuing operations was INR 24.55 compared to INR 5.94 a year ago.
For the full year, sales was INR 126,675.8 million compared to INR 115,992.6 million a year ago. Revenue was INR 129,784.2 million compared to INR 1,181,534 million a year ago. Net income was INR 17,957.7 million compared to INR 9,841.7 million a year ago. Basic earnings per share from continuing operations was INR 150.19 compared to INR 82.31 a year ago. Diluted earnings per share from continuing operations was INR 150.19 compared to INR 82.31 a year ago.
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
ALKEM LABORATORIES LIMITED 
